Past reports on severe COVID‐19 also detected AIM + CD4 Treg and Th17 subsets, including one study on B‐mAB post‐therapy T‐cell immunity in 46 subjects (unspecified for malignancies).6, 14. Here, CD4 is linked to cancer.